BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity, Heart Failure at ADA

BioAge Labs (NASDAQ: BIOA) announced new preclinical data presentation at ADA's 85th Scientific Sessions regarding their APJ agonist treatment for diabetic obesity and heart failure. The data shows that APJ activation, combined with incretin therapy, demonstrated significant benefits in preclinical models. Key findings include improved glycemic control with a 25% enhancement in glucose tolerance and reduced HbA1c levels in diabetic obesity models. In heart failure models, the treatment showed cardioprotective effects and reduced cardiac hypertrophy. The company is developing both oral and injectable APJ agonist formulations, targeting an IND filing for 2026. The research suggests APJ agonists could act as exercise mimetics, potentially doubling the weight loss effects of GLP-1 receptor agonists while improving body composition and muscle function.

https://www.stocktitan.net/news/BIOA/bio-age-labs-to-present-preclinical-data-on-apj-agonism-for-diabetic-wax79l84qxi8.html